Bladder cancer
First-line therapy of synchronous and metachronous metastatic UCa

Charles (67 years old)

Charles, 67 years old, is a dedicated chef and good-hearted person. He is training his adoptive son to succeed him in the restaurant where he works.

Recently, he was diagnosed with urothelial muscle-invasive bladder cancer (MIBC) cT2N0M0. He underwent immediate radical cystectomy (RC) without receiving neoadjuvant chemotherapy. The pathological review of the RC specimen indicated pT3 pN0 (0/10) R0, PD-L1-negative. Following RC, the patient received adjuvant dd-MVAC, which was well tolerated.

He presents with liver metastases 5 months after completing adjuvant chemotherapy.

Assessment summary:

  • Former smoker (20 pack years)
  • No relevant medical history
  • ECOG PS: 0
  • Haemoglobin: 12.5 g/dl
  • Peripheral neuropathy grade 1
  • No hearing impairment
  • GFR: 70 ml/min
  • CT scan reveals diffuse liver metastases, biopsy compatible with UCa
  • Activating FGFR3 mutation in diagnostic biopsy specimen

Which of the following treatment options would you choose for this patient?